Common Contracts

4 similar Consulting Agreement contracts by Elevai Labs Inc., PMGC Holdings Inc.

SECOND AMENDED AND RESTATED CONSULTING AGREEMENT FOR NON-EMPLOYEE CHIEF EXECUTIVE OFFICER
Consulting Agreement • February 12th, 2025 • PMGC Holdings Inc. • Pharmaceutical preparations • British Columbia

This Second Amended and Restated Consulting Agreement (this “Agreement”), effective as of October 25, 2024 (“Effective Date”), is entered into by and between Elevai Labs Inc., a Delaware corporation fka Reactive Medical Labs, Inc. (“Company”), and GB Capital Ltd, a British Columbia, Canada Corporation (“Consultant”).

SECOND AMENDED AND RESTATED CONSULTING AGREEMENT FOR NON-EXECUTIVE CHAIRMAN
Consulting Agreement • February 12th, 2025 • PMGC Holdings Inc. • Pharmaceutical preparations • California

This Second Amended and Restated Consulting Agreement (this “Second A&R Agreement”), effective as of October 25, 2024 (“Effective Date”), is entered into by and between Elevai Labs Inc., a Delaware corporation fka Reactive Medical Labs, Inc. (“Company”), and NorthStrive Companies Inc., a California corporation (“Consultant”).

SECOND AMENDED AND RESTATED CONSULTING AGREEMENT FOR NON-EMPLOYEE CHIEF EXECUTIVE OFFICER
Consulting Agreement • October 31st, 2024 • Elevai Labs Inc. • Pharmaceutical preparations • British Columbia

This Second Amended and Restated Consulting Agreement (this “Agreement”), effective as of October 25, 2024 (“Effective Date”), is entered into by and between Elevai Labs Inc., a Delaware corporation fka Reactive Medical Labs, Inc. (“Company”), and GB Capital Ltd, a British Columbia, Canada Corporation (“Consultant”).

SECOND AMENDED AND RESTATED CONSULTING AGREEMENT FOR NON-EXECUTIVE CHAIRMAN
Consulting Agreement • October 31st, 2024 • Elevai Labs Inc. • Pharmaceutical preparations • California

This Second Amended and Restated Consulting Agreement (this “Second A&R Agreement”), effective as of October 25, 2024 (“Effective Date”), is entered into by and between Elevai Labs Inc., a Delaware corporation fka Reactive Medical Labs, Inc. (“Company”), and NorthStrive Companies Inc., a California corporation (“Consultant”).